Cambridge Cancer Genomics Company

Cambridge Cancer Genomics develops precision oncology solutions to transform the way cancer patients are treated. Using simple blood draws, CCG shortens the time required to know whether treatment is working, buying the clinician more time to alter treatment and reduce unnecessary side effects. The technology can detect relapse earlier than standard of care, predict response to therapy, and decrease ineffective treatment regimens. Over time, CCG will be able to better predict the best therapeutic strategy for cancer patients before they even begin treatment. Cambridge Cancer Genomics was founded on 2016 and is headquartered in Cambridge, England.

Estimated Revenue: Less than $1M
Funding Status: M&A
Headquarters: Cambridge, Cambridgeshire, United Kingdom
Total Funding: 22035000
Last Funding Date: 2018-12-31
Investors Number: 10.0
Founded Date: 2016-01-01
Technology: Medical BioTech
Industry: Medical BioTech
Last Funding Type: Seed
Employee Number: 11-50